Choroideremia Market - Global Forecast 2026-2032

The Choroideremia Market is positioned for sustained advancement, as evolving therapeutic strategies and global collaborations drive innovation and shape market priorities. Senior executives benefit from nuanced insights that reveal not just market acceleration but the operational dynamics underpinning durable patient access in this rare ophthalmic segment.

Market Snapshot: Choroideremia Market Growth

The choroideremia therapeutics market expanded from USD 406.63 million in 2025 to USD 461.68 million in 2026, and is projected to continue growing at a CAGR of 14.14%, reaching USD 1.02 billion by 2032.

Scope & Segmentation

This analysis provides a multidimensional view of the choroideremia market, focusing on genetic mechanisms, targeted therapies, and operational challenges. Key segmentation areas include:

Therapy Modalities: Gene therapies utilizing adeno-associated virus and lentiviral vectors; neuroprotective and anti-inflammatory pharmacotherapies.
Developmental Phases: Pipeline spanning preclinical, Phase I, Phase II, and Phase III clinical trials, each with distinct evidence and regulatory needs.
Delivery Routes: Intravitreal injections supported by advanced microinjectors; subretinal surgical approaches for direct retinal targeting.
Care Settings: Hospitals and tertiary referral centers equipped for complex ocular procedures; research institutes focusing on trial design and biomarker validation; specialty clinics optimized for decentralized treatment and follow-up.
Distribution Pathways: Hospital, specialty, and online pharmacies, along with manufacturer-direct fulfillment and third-party digital platforms, each ensuring regulatory compliance and cold-chain integrity.
Regions: North America, Europe, Middle East & Africa, Asia-Pacific—each characterized by unique regulatory environments, access patterns, and manufacturing strengths.

Key Takeaways for Strategic Decision-Makers

Continued scientific progress in gene replacement and neuroprotection is reshaping clinical trial endpoints, patient selection, and therapeutic durability for choroideremia.
Adoption of advanced delivery systems, such as minimally invasive intravitreal injection and precision microinjectors, is reducing procedural burdens and facilitating broader patient access.
Evolving regulatory frameworks now accommodate smaller, biomarker-driven studies and conditional approvals, aligning with rare disease development realities while increasing expectations for post-market evidence.
Growth in scalable viral vector manufacturing and robust supply chain strategies is addressing bottlenecks, mitigating risks from single-source suppliers, and enabling faster access following regulatory milestones.
Payer requirements emphasize demonstrated long-term outcomes and innovative contracting, driving developers to substantiate value and efficiency, especially amidst mounting cost pressures and reimbursement scrutiny.
Collaborative models—linking biotech developers, CDMOs, clinical networks, and advocacy groups—accelerate translational progress and help navigate scientific, operational, and regulatory challenges across global territories.

Tariff Impact: Market Implications of 2025 US Tariff Adjustments

Recent US tariff adjustments are influencing choroideremia supply chains, manufacturing decisions, and patient access. Cost increases or administrative delays in critical raw materials, viral vector components, and delivery devices compel organizations to reassess supplier diversification, regional manufacturing, and logistics strategies. Shifts in sourcing and potential regulatory re-evaluations due to altered device procurement add complexity to clinical program execution. In parallel, hospitals and clinics facing higher acquisition costs may adjust procurement and tendering approaches, while payers assess efficiency gains or outcomes-based solutions to maintain patient access.

Methodology & Data Sources

This report integrates primary research from peer-reviewed clinical literature, global trial registries, expert interviews across retinal surgery and manufacturing, and in-depth supply chain mapping. Analytical rigor is maintained through comparative platform evaluations, triangulation of key insights, and adherence to quality assurance protocols for transparency and reliability.

Why This Report Matters

Guides strategic investment and clinical planning by clarifying segment trends, regulatory trajectories, and operational risks specific to choroideremia therapies.
Equips decision-makers with actionable recommendations to strengthen platform robustness, supply resilience, and regulatory alignment for sustainable market entry and patient access.
Supports risk mitigation by illuminating potential tariff impacts and evolving manufacturing dynamics, enabling proactive responses aligned with market realities.

Conclusion

Delivering durable treatment options for choroideremia requires harmonizing scientific innovation, operational excellence, and strategic partnerships. This report underscores pivotal insights for leaders navigating the evolving landscape of rare retinal therapeutics.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025

8. Choroideremia Market, by Therapy Type

8.1. Gene Therapy
8.1.1. Aav Vector
8.1.2. Lentiviral Vector
8.2. Pharmacotherapy
8.2.1. Anti Inflammatory Agents
8.2.2. Neuroprotective Agents

9. Choroideremia Market, by Development Stage

9.1. Phase I
9.2. Phase II
9.3. Phase III
9.4. Preclinical Research

10. Choroideremia Market, by Route Of Administration

10.1. Intravitreal Injection
10.1.1. Conventional Syringe
10.1.2. Microinjector
10.2. Subretinal Injection

11. Choroideremia Market, by End User

11.1. Hospitals
11.2. Research Institutes
11.3. Specialty Clinics

12. Choroideremia Market, by Distribution Channel

12.1. Hospital Pharmacies
12.2. Online Pharmacies
12.2.1. Manufacturer Direct
12.2.2. Third Party Platforms
12.3. Specialty Pharmacies

13. Choroideremia Market, by Region

13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific

14. Choroideremia Market, by Group

14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO

15. Choroideremia Market, by Country

15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea

16. United States Choroideremia Market
17. China Choroideremia Market

18. Competitive Landscape

18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. 4D Molecular Therapeutics
18.6. Adverum Biotechnologies
18.7. Amicus Therapeutics
18.8. Applied Genetic Technologies Corporation
18.9. Asper Biogene LLC
18.10. Astellas Pharma Inc.
18.11. Biogen Inc.
18.12. Copernicus Therapeutics, Inc.
18.13. Curative Biotechnology, Inc.
18.14. Editas Medicine
18.15. GenSight Biologics S.A.
18.16. Hemera Biosciences
18.17. Kiora Pharmaceuticals, Inc.
18.18. MeiraGTx Holdings plc
18.19. Merck KGaA
18.20. Novartis AG
18.21. Oxurion
18.22. Pfizer Inc.
18.23. Pixium Vision SA
18.24. REGENXBIO Inc.
18.25. Spark Therapeutics, Inc. by F. Hoffmann-La Roche Ltd

List of Figures

FIGURE 1. GLOBAL CHOROIDEREMIA MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL CHOROIDEREMIA MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL CHOROIDEREMIA MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL CHOROIDEREMIA MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL CHOROIDEREMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL CHOROIDEREMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL CHOROIDEREMIA MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CHOROIDEREMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL CHOROIDEREMIA MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CHOROIDEREMIA MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL CHOROIDEREMIA MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES CHOROIDEREMIA MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA CHOROIDEREMIA MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL CHOROIDEREMIA MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL CHOROIDEREMIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL CHOROIDEREMIA MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL CHOROIDEREMIA MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL CHOROIDEREMIA MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL CHOROIDEREMIA MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL CHOROIDEREMIA MARKET SIZE, BY AAV VECTOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL CHOROIDEREMIA MARKET SIZE, BY AAV VECTOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL CHOROIDEREMIA MARKET SIZE, BY AAV VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CHOROIDEREMIA MARKET SIZE, BY LENTIVIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CHOROIDEREMIA MARKET SIZE, BY LENTIVIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL CHOROIDEREMIA MARKET SIZE, BY LENTIVIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL CHOROIDEREMIA MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL CHOROIDEREMIA MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL CHOROIDEREMIA MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL CHOROIDEREMIA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL CHOROIDEREMIA MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL CHOROIDEREMIA MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL CHOROIDEREMIA MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL CHOROIDEREMIA MARKET SIZE, BY NEUROPROTECTIVE AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL CHOROIDEREMIA MARKET SIZE, BY NEUROPROTECTIVE AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL CHOROIDEREMIA MARKET SIZE, BY NEUROPROTECTIVE AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL CHOROIDEREMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL CHOROIDEREMIA MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL CHOROIDEREMIA MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL CHOROIDEREMIA MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL CHOROIDEREMIA MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL CHOROIDEREMIA MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL CHOROIDEREMIA MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL CHOROIDEREMIA MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL CHOROIDEREMIA MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL CHOROIDEREMIA MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL CHOROIDEREMIA MARKET SIZE, BY PRECLINICAL RESEARCH, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL CHOROIDEREMIA MARKET SIZE, BY PRECLINICAL RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL CHOROIDEREMIA MARKET SIZE, BY PRECLINICAL RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL CHOROIDEREMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL CHOROIDEREMIA MARKET SIZE, BY INTRAVITREAL INJECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL CHOROIDEREMIA MARKET SIZE, BY INTRAVITREAL INJECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL CHOROIDEREMIA MARKET SIZE, BY INTRAVITREAL INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL CHOROIDEREMIA MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL CHOROIDEREMIA MARKET SIZE, BY CONVENTIONAL SYRINGE, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL CHOROIDEREMIA MARKET SIZE, BY CONVENTIONAL SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL CHOROIDEREMIA MARKET SIZE, BY CONVENTIONAL SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL CHOROIDEREMIA MARKET SIZE, BY MICROINJECTOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL CHOROIDEREMIA MARKET SIZE, BY MICROINJECTOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL CHOROIDEREMIA MARKET SIZE, BY MICROINJECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL CHOROIDEREMIA MARKET SIZE, BY SUBRETINAL INJECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL CHOROIDEREMIA MARKET SIZE, BY SUBRETINAL INJECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL CHOROIDEREMIA MARKET SIZE, BY SUBRETINAL INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL CHOROIDEREMIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL CHOROIDEREMIA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL CHOROIDEREMIA MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL CHOROIDEREMIA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL CHOROIDEREMIA MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL CHOROIDEREMIA MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL CHOROIDEREMIA MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL CHOROIDEREMIA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL CHOROIDEREMIA MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL CHOROIDEREMIA MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL CHOROIDEREMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL CHOROIDEREMIA MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL CHOROIDEREMIA MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL CHOROIDEREMIA MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL CHOROIDEREMIA MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL CHOROIDEREMIA MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL CHOROIDEREMIA MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL CHOROIDEREMIA MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL CHOROIDEREMIA MARKET SIZE, BY MANUFACTURER DIRECT, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL CHOROIDEREMIA MARKET SIZE, BY MANUFACTURER DIRECT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL CHOROIDEREMIA MARKET SIZE, BY MANUFACTURER DIRECT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL CHOROIDEREMIA MARKET SIZE, BY THIRD PARTY PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL CHOROIDEREMIA MARKET SIZE, BY THIRD PARTY PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL CHOROIDEREMIA MARKET SIZE, BY THIRD PARTY PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL CHOROIDEREMIA MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL CHOROIDEREMIA MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL CHOROIDEREMIA MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL CHOROIDEREMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. AMERICAS CHOROIDEREMIA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 79. AMERICAS CHOROIDEREMIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 80. AMERICAS CHOROIDEREMIA MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 81. AMERICAS CHOROIDEREMIA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 82. AMERICAS CHOROIDEREMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 83. AMERICAS CHOROIDEREMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 84. AMERICAS CHOROIDEREMIA MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 85. AMERICAS CHOROIDEREMIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 86. AMERICAS CHOROIDEREMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 87. AMERICAS CHOROIDEREMIA MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA CHOROIDEREMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. NORTH AMERICA CHOROIDEREMIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 90. NORTH AMERICA CHOROIDEREMIA MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 91. NORTH AMERICA CHOROIDEREMIA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 92. NORTH AMERICA CHOROIDEREMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 93. NORTH AMERICA CHOROIDEREMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 94. NORTH AMERICA CHOROIDEREMIA MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 95. NORTH AMERICA CHOROIDEREMIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 96. NORTH AMERICA CHOROIDEREMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 97. NORTH AMERICA CHOROIDEREMIA MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 98. LATIN AMERICA CHOROIDEREMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. LATIN AMERICA CHOROIDEREMIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 100. LATIN AMERICA CHOROIDEREMIA MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 101. LATIN AMERICA CHOROIDEREMIA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 102. LATIN AMERICA CHOROIDEREMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 103. LATIN AMERICA CHOROIDEREMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 104. LATIN AMERICA CHOROIDEREMIA MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 105. LATIN AMERICA CHOROIDEREMIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 106. LATIN AMERICA CHOROIDEREMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 107. LATIN AMERICA CHOROIDEREMIA MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA CHOROIDEREMIA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA CHOROIDEREMIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA CHOROIDEREMIA MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA CHOROIDEREMIA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA CHOROIDEREMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA CHOROIDEREMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA CHOROIDEREMIA MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA CHOROIDEREMIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA CHOROIDEREMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA CHOROIDEREMIA MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 118. EUROPE CHOROIDEREMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 119. EUROPE CHOROIDEREMIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 120. EUROPE CHOROIDEREMIA MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 121. EUROPE CHOROIDEREMIA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 122. EUROPE CHOROIDEREMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 123. EUROPE CHOROIDEREMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 124. EUROPE CHOROIDEREMIA MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 125. EUROPE CHOROIDEREMIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 126. EUROPE CHOROIDEREMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 127. EUROPE CHOROIDEREMIA MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 128. MIDDLE EAST CHOROIDEREMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. MIDDLE EAST CHOROIDEREMIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 130. MIDDLE EAST CHOROIDEREMIA MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 131. MIDDLE EAST CHOROIDEREMIA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 132. MIDDLE EAST CHOROIDEREMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 133. MIDDLE EAST CHOROIDEREMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 134. MIDDLE EAST CHOROIDEREMIA MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 135. MIDDLE EAST CHOROIDEREMIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 136. MIDDLE EAST CHOROIDEREMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 137. MIDDLE EAST CHOROIDEREMIA MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 138. AFRICA CHOROIDEREMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 139. AFRICA CHOROIDEREMIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 140. AFRICA CHOROIDEREMIA MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 141. AFRICA CHOROIDEREMIA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 142. AFRICA CHOROIDEREMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 143. AFRICA CHOROIDEREMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 144. AFRICA CHOROIDEREMIA MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 145. AFRICA CHOROIDEREMIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 146. AFRICA CHOROIDEREMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 147. AFRICA CHOROIDEREMIA MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC CHOROIDEREMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC CHOROIDEREMIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 150. ASIA-PACIFIC CHOROIDEREMIA MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC CHOROIDEREMIA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 152. ASIA-PACIFIC CHOROIDEREMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 153. ASIA-PACIFIC CHOROIDEREMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC CHOROIDEREMIA MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC CHOROIDEREMIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 156. ASIA-PACIFIC CHOROIDEREMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 157. ASIA-PACIFIC CHOROIDEREMIA MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 158. GLOBAL CHOROIDEREMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 159. ASEAN CHOROIDEREMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 160. ASEAN CHOROIDEREMIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 161. ASEAN CHOROIDEREMIA MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 162. ASEAN CHOROIDEREMIA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 163. ASEAN CHOROIDEREMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 164. ASEAN CHOROIDEREMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 165. ASEAN CHOROIDEREMIA MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 166. ASEAN CHOROIDEREMIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 167. ASEAN CHOROIDEREMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 168. ASEAN CHOROIDEREMIA MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 169. GCC CHOROIDEREMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 170. GCC CHOROIDEREMIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 171. GCC CHOROIDEREMIA MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 172. GCC CHOROIDEREMIA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 173. GCC CHOROIDEREMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 174. GCC CHOROIDEREMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 175. GCC CHOROIDEREMIA MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 176. GCC CHOROIDEREMIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 177. GCC CHOROIDEREMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 178. GCC CHOROIDEREMIA MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 179. EUROPEAN UNION CHOROIDEREMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 180. EUROPEAN UNION CHOROIDEREMIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 181. EUROPEAN UNION CHOROIDEREMIA MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION CHOROIDEREMIA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 183. EUROPEAN UNION CHOROIDEREMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 184. EUROPEAN UNION CHOROIDEREMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION CHOROIDEREMIA MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION CHOROIDEREMIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION CHOROIDEREMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION CHOROIDEREMIA MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 189. BRICS CHOROIDEREMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 190. BRICS CHOROIDEREMIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 191. BRICS CHOROIDEREMIA MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 192. BRICS CHOROIDEREMIA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 193. BRICS CHOROIDEREMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 194. BRICS CHOROIDEREMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 195. BRICS CHOROIDEREMIA MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 196. BRICS CHOROIDEREMIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 197. BRICS CHOROIDEREMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 198. BRICS CHOROIDEREMIA MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 199. G7 CHOROIDEREMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 200. G7 CHOROIDEREMIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 201. G7 CHOROIDEREMIA MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 202. G7 CHOROIDEREMIA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 203. G7 CHOROIDEREMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 204. G7 CHOROIDEREMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 205. G7 CHOROIDEREMIA MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 206. G7 CHOROIDEREMIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 207. G7 CHOROIDEREMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 208. G7 CHOROIDEREMIA MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 209. NATO CHOROIDEREMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 210. NATO CHOROIDEREMIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 211. NATO CHOROIDEREMIA MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 212. NATO CHOROIDEREMIA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 213. NATO CHOROIDEREMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 214. NATO CHOROIDEREMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 215. NATO CHOROIDEREMIA MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 216. NATO CHOROIDEREMIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 217. NATO CHOROIDEREMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 218. NATO CHOROIDEREMIA MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 219. GLOBAL CHOROIDEREMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 220. UNITED STATES CHOROIDEREMIA MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 221. UNITED STATES CHOROIDEREMIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 222. UNITED STATES CHOROIDEREMIA MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 223. UNITED STATES CHOROIDEREMIA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 224. UNITED STATES CHOROIDEREMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 225. UNITED STATES CHOROIDEREMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 226. UNITED STATES CHOROIDEREMIA MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 227. UNITED STATES CHOROIDEREMIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 228. UNITED STATES CHOROIDEREMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 229. UNITED STATES CHOROIDEREMIA MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 230. CHINA CHOROIDEREMIA MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 231. CHINA CHOROIDEREMIA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 232. CHINA CHOROIDEREMIA MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 233. CHINA CHOROIDEREMIA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 234. CHINA CHOROIDEREMIA MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 235. CHINA CHOROIDEREMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 236. CHINA CHOROIDEREMIA MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
TABLE 237. CHINA CHOROIDEREMIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 238. CHINA CHOROIDEREMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 239. CHINA CHOROIDEREMIA MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Choroideremia market report include:

4D Molecular Therapeutics
Adverum Biotechnologies
Amicus Therapeutics
Applied Genetic Technologies Corporation
Asper Biogene LLC
Astellas Pharma Inc.
Biogen Inc.
Copernicus Therapeutics, Inc.
Curative Biotechnology, Inc.
Editas Medicine
GenSight Biologics S.A.
Hemera Biosciences
Kiora Pharmaceuticals, Inc.
MeiraGTx Holdings plc
Merck KGaA
Novartis AG
Oxurion
Pfizer Inc.
Pixium Vision SA
REGENXBIO Inc.
Spark Therapeutics, Inc. by F. Hoffmann-La Roche Ltd

Table Information

Report Attribute	Details
No. of Pages	196
Published	January 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 461.68 Million
Forecasted Market Value ( USD ) by 2032	$ 1020 Million
Compound Annual Growth Rate	14.1%
Regions Covered	Global
No. of Companies Mentioned	22

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3400EUR$3,939USD£2,955GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3667EUR$4,249USD£3,187GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€4971EUR$5,759USD£4,320GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6015EUR$6,969USD£5,228GBP

Market Snapshot: Choroideremia Market Growth

Scope & Segmentation

Key Takeaways for Strategic Decision-Makers

Tariff Impact: Market Implications of 2025 US Tariff Adjustments

Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Choroideremia - Pipeline Insight, 2025

Ophthalmic Drugs: Market Share, and Growth Analysis by Product Type (Anti-Glaucoma Drugs, Anti-Allergy Drugs, Anti-infective Drugs, Ophthalmic Surgical Devices), Application, End User, Technology

Ophthalmics Collaboration and Licensing Deals 2019-2025

Gene Therapy for Ocular Rare Disease - Market Insight, Epidemiology, and Market Forecast - 2034

Uveitis Treatment Market - Global Forecast 2026-2032